SCA
REGN icon

SAC Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

SAC Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-65,232
Closed -$19.6M – 798
2014
Q1 		$19.6M Buy
65,232
+36,928
+130% +$11.4M 0.1% 271
2013
Q4 		$7.79M Buy
28,304
+26,884
+1,893% +$7.73M 0.05% 425
2013
Q3 		$444K Sell
1,420
-31,732
-96% -$8.35M ﹤0.01% 1204
2013
Q2 		$7.46M Buy
+33,152
New +$7.72M 0.04% 435

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAC Capital Advisors's REGN Position: Q2 2014 in Review

SAC Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2014, closing a stake of 65,232 shares — an estimated $19.6M sold.

SAC Capital Advisors first reported a position in REGN in Q2 2013 and held it in 4 quarters. The position peaked at $19.6M in Q1 2014. 447 funds tracked by Wall St. Rank hold REGN as of Q2 2014.

  • SAC Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 65,232 Regeneron Pharmaceuticals shares in Q2 2014, an estimated $19.6M.
  • SAC Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Regeneron Pharmaceuticals position peaked at $19.6M in Q1 2014.
  • 447 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.